Best Life Sciences Companies in Oslo, Norway
The 82 best Life Sciences companies in Oslo, Norway in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Calluna Pharma.
Our analysis of 576 Life Sciences companies
$91.7b in tracked funding; 70% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Oslo
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Calluna Pharma Developer of therapeutics for inflammatory and fibrotic diseases | $82M | 28 mo ago | — | Jonas Hallen Founder | Series A | — | — |
| 2 | Nordic Nanovector Developer of antibody radionuclide conjugates for haematological cancers | $52M | 53 mo ago | 40 40 → 24 (-40%) | — | Public | 98 patents Radioimmunoconjugate antibodies targeting CD37 for lymphoma therapy | 1 job opening |
| 3 | Ultimovacs Developer of next-generation cell therapies for solid tumors | $32M | 55 mo ago | 25 | — | Public | 29 patents Therapeutic cancer vaccines combining telomerase antigens with immune‑checkpoint inhibitors | — |
| 4 | Oncoinvent Developer of radioisotope-based anti-cancer therapeutics | $31M | 73 mo ago | 27 27 → 50 (+85%) | — | Public | 43 patents Targeted alpha‑emitting radiopharmaceuticals and antibody‑based cancer therapeutics | — |
| 5 | Arctic Bioscience Developer of the drug for psoriasis | $30M | 64 mo ago | 13 | Christer Valderhaug CEO | Public | — | 1 launch · 1 partnership · 1 expansion |
| 6 | Algeta Developing alpha particle-emitting pharmaceutical with an anti-tumor effect for the treatment of cancer. | $29M | 249 mo ago | 175 | — | Acquired | 56 patents Targeted alpha‑emitting radiopharmaceuticals (Thorium‑227) for soft‑tissue and bone cancer therapy | — |
| 7 | Lytix Biopharma Developer of oncolytic peptide immunotherapy for solid tumors | $20M | 18 mo ago | 7 | — | Public | 162 patents Peptide-based oncolytic and immunotherapy formulations using chitosan delivery systems | — |
| 8 | EXACT Therapeutics Provider of sonoporation platform for diagnosis of multiple diseases | $16M | 71 mo ago | 7 | Masha Stromme CEO | Late Stage | 48 patents Ultrasound-based drug delivery and ablation technologies with dose calculation software. | — |
| 9 | ConCordix Manufacturer of vitamin and supplements for the nutraceutical and dietary supplement industry | $15M | 191 mo ago | — | Klaus Neumann Chief Executive Officer | Series A | — | — |
| 10 | Arxx Therapeutics Developer of monoclonal antibody for fibrotic disease | $13M | 63 mo ago | 2 | Jonas Hallen Co-Founder | Seed | 13 patents Humanized therapeutic antibodies targeting S100A4 for fibrosis and systemic sclerosis treatment | — |
| 11 | SantoSolve Develops targeted pain therapeutics | $12M | 199 mo ago | 8 | — | Deadpooled | 25 patents Strontium-based anti‑inflammatory and analgesic formulations for topical soft‑tissue pain relief | — |
| 12 | Zelluna Immunotherapy Developer of TCR-based therapies for a wide range of cancer types | $8M | 45 mo ago | 18 18 → 23 (+28%) | — | Series B | 5 patents Engineered NK cell therapies and MAGE‑A4 specific TCR‑modified T cell immunotherapies | 1 job opening |
| 13 | OncoImmunity Developer of machine-learning based software for personalized cancer immunotherapy | $7M | 55 mo ago | 16 | Richard Stratford Co-founder and Advisor | Acquired | 4 patents Predictive peptide selection for MHC presentation in cancer immunotherapy and vaccine design | 1 job opening |
| 14 | CellCura Cell Culture reagent provider | $4M | 148 mo ago | — | Pål Bråthen CEO | Deadpooled | 2 patents Automated sperm analysis and imaging diagnostics for reproductive health | — |
| 15 | Biovotec Developing biological wound dressing based on the hen eggshell membrane | $4M | 80 mo ago | 5 | Henri-Pierre Suso Co founder and CTO at Biovotec | Funding Raised | 45 patents Eggshell membrane-derived biomaterials for wound healing and peptide delivery systems. | — |
| 16 | Clavis Pharma Developer of novel small molecule therapeutics for cancer | $3M | 173 mo ago | — | Carlos Roig Founder | Deadpooled | 84 patents Antibody therapeutics targeting ENT1 and prodrug formulations of nucleoside analogs and glucocorticoid esters for cancer and infla | — |
| 17 | EpiGuard Developer of medical isolation and transportation systems | $3M | 55 mo ago | 17 | Fridtjof Heyerdahl Founder & CMO | Funding Raised | 4 patents Secure patient transport systems and isolation devices for medical transport | — |
| 18 | SoftOx Developer of topical antiseptic products for chronic wounds | $2M | 44 mo ago | 21 21 → 13 (-38%) | Geir Hermod Almas CEO | Public | 11 patents Formulating and dispensing hypochlorous‑acid based disinfectants and biofilm treatments. | — |
| 19 | OstomySecure Developer of a transcutaneous implant evacuation system for ileostomy patients | $2M | 89 mo ago | — | Bente Buverud Founder | Acquired | — | — |
| 20 | Augere Medical Provider of AI-based cancer detection device | $2M | 19 mo ago | 4 | — | Seed | 6 patents Real-time video object detection algorithms for medical imaging and diagnostics | — |
| 21 | Pre Diagnostics Blood based diagnostics for Alzheimer's disease. | $2M | 54 mo ago | 8 | — | Series A | — | 1 partnership |
| 22 | Resani Developer of hand sanitizing technology for hospitals | $1M | 37 mo ago | 3 | — | Seed | 5 patents Hand hygiene devices and methods for personal sanitization | — |
| 23 | Bio-Me Developer of a platform for gut microbiome analysis | $1M | 42 mo ago | 12 | Morten Isaksen CEO | Seed | — | 1 partnership |
| 24 | ClexBio Developer of microfluidic chip for laboratory purposes | $1M | 19 mo ago | 4 | Armend Hati Co-Founder & CEO | Seed | — | — |
| 25 | Nykode Therapeutics Developer of vaccines and immunotherapeutics for cancer and infectious diseases | $961K | 135 mo ago | 102 102 → 73 (-28%) | Agnete Fredriksen Co-Founder & Chief Business Officer | Public | 110 patents Protein-based immunogenic constructs and neoepitope vaccines for cancer and infectious disease therapy | — |
| 26 | Circio Developer of immunotherapies for cancer treatment | $956K | 18 mo ago | 17 | Erik Digman Wiklund Chief Executive Officer | Public | — | 1 partnership |
| 27 | Cardinor Provider of biomarker-based assays for cardiovascular diseases | $922K | 62 mo ago | 2 | — | Seed | 2 patents Immunoassay techniques for measuring secretoneurin peptide levels | — |
| 28 | Age Labs Developer of molecular diagnostic solutions for the detection of age-related diseases | $876K | 74 mo ago | 4 | Karl Trygve Kalleberg Co-Founder & CTO | Seed | 5 patents Diagnostic screening assays for rheumatoid arthritis and severe COVID-19 susceptibility biomarkers | — |
| 29 | Hy5 Hydraulic prosthesis for amputees | $514K | 66 mo ago | — | Christian Stray Co-Founder & CEO | Seed | — | — |
| 30 | Hubro Therapeutics Developer of immunotherapies for cancer treatment | $164K | 83 mo ago | 5 | Jon Eriksen CEO | Deadpooled | 45 patents Design and synthesis of therapeutic peptides and diagnostic primer cocktails | — |
| 31 | RemovAid Developer of medical devices for the removal of sub-dermal implants | $117K | 90 mo ago | 5 | Marte Bratlie Founder | Acquired | 31 patents Surgical devices and methods for extracting subdermal medical implants | — |
| 32 | ODI Medical Developer of technology to assess microcirculation | $114K | 83 mo ago | 5 | Knut Kvernebo Founder | Funding Raised | 15 patents Non‑invasive microcirculation and oxygen saturation monitoring devices and capillary analysis probes. | — |
| 33 | Labrida Provider of medical device for professional cleaning of dental implants and teeth | $108K | 126 mo ago | 6 | Liv Ostbye CEO | Funding Raised | 22 patents Dental therapeutic hydrogels for preventing and treating periodontal and peri‑implant diseases | 1 launch |
| 34 | Photocure Provider of photodynamic therapy solutions for bladder, colorectal, and cervical cancer | — | 73 mo ago | 155 | — | Public | 6 patents Intracellular delivery of therapeutic agents and photodynamic therapy using 5‑ALA ester photosensitizers | — |
| 35 | Genetic Analysis Developer of diagnostic solutions for microbial analysis | — | 114 mo ago | 22 22 → 20 (-9%) | — | Series B | 52 patents Microbiome-based diagnostics and companion tests for IBS and gut dysbiosis | — |
Top 12 Life Sciences companies in Oslo
#1
Public · Oslo, Oslo · founded 2003 · 7 employees$20.4Mraised▾
Lytix Biopharma develops oncolytic immunotherapies. Its lead candidate is LTX-315, an oncolytic peptide is being developed to treat solid cancer (phase I/II). It is also developing LTX-315 in combination with checkpoint inhibitors to treat cancer (preclinical/phase1) and a candidate under investigation for multidrug-resistant infections.
- Dec 2024Post IPO$9M
- Oct 2023Grant (prize money)$1.3M
- Aug 2017Series A$758.6K
- Dec 2015Series A$9.2M
#2
Seed · Oslo, Oslo · founded 2018 · 4 employees$2.1Mraised▾
Augere provides an AI-based cancer detection device. It analyses video in real-time. It can connect to any vendor's equipment. It gives the endoscopist a real-time probability of early-stage lesions.
- Nov 2024Seed$2.1M
#3
Series A · Oslo, Oslo · founded 2024$81.7Mraised▾
Developer of therapeutics for inflammatory and fibrotic diseases. The company is developing a pipeline of antibodies targeting a comprehensive range of disease-associated with precision targeting of upstream innate immune amplifiers for inflammatory and fibrotic diseases.
- Jan 2024Series A$81.7M
#4
Seed · Oslo, Oslo · founded 2020 · 4 employees$1.2Mraised▾
Developer of a microfluidic chip for laboratory purposes. It uses hydrogel technology CLEX that allows hydrogel formation with, both, precise control and exceptional biocompatibility. This enables users to use microfluidic devices to form hydrogel microstructures containing delicate biological cargo such as living cells.
- Nov 2024Seed—
- Jul 2021Grant (prize money)$1M
- Jul 2021Seed$1.2M
#5
Public · Oslo, Oslo · founded 2010 · 17 employees$956.4Kraised▾
Developer of immunotherapies for cancer treatment. It offers circular RNA platform for developing medicines based on a modular genetic cassette design for expression of therapeutic proteins directly into cancer cells. It provides a lead candidate ONCOS-102 a monotherapy and in combinations with checkpoint inhibitors for melanoma, and TG01 is an immunotherapy targeting KRAS driver mutations for pancreatic cancer.
- Dec 2024Post IPO$956.4K
#6
Public · Oslo, Oslo · founded 2009 · 40 employees$51.7Mraised▾
Developer of antibody radionuclide conjugates for hematological cancers. The company's lead product includes Betalutin, an ARC that comprises a tumor-seeking anti-CD37 antibody conjugated to a low-intensity radionuclide (Lutetium 177). It is used to treat blood cancer non-Hodgkin Lymphoma.
- Jan 2022Post IPO—
- Feb 2021Post IPO—
- Sep 2020Post IPO$24.9M
- Dec 2019Post IPO$1.3M
#7
Public · Oslo, Oslo · founded 2011 · 25 employees$32.3Mraised▾
Developer of next-generation cell therapies for solid tumors. The company has developed an immune-stimulatory vaccine UV1 (peptide epitopes from hTERT) vaccine targeting hTERT fragment expressing cancer cells to activate the immune response especially T-helper cells. It helps in treating prostate cancer and non-small cell lung carcinoma.
- Oct 2021Post IPO$32.3M
#8
Public · Oslo, Oslo · founded 2011 · 13 employees$29.8Mraised▾
Developer of the drug for psoriasis. The product HRO350 is a phospholipid drug for the oral treatment of psoriasis based on bioactive marine compounds extracted from herring roe. Also, have herring caviar oil and omega-3 dietary supplement Romega.
- Feb 2021Post IPO$29.7M
- Aug 2019Grant (prize money)$55.4K
#9
Series B · Oslo, Oslo · founded 2016 · 18 employees$8.4Mraised▾
Developer of TCR-based therapies for a wide range of cancer types. It offers T-cell receptor-guided natural killer (NK) cell therapies for solid tumors and multiple cancers.
- Aug 2022Series B—
- Jun 2020Series A$8.4M
- Jun 2020Grant (prize money)—
- 2016Seed—
#10
Public · Oslo, Oslo · founded 2010 · 27 employees$30.7Mraised▾
Oncoinvent is developing radiotherapeutic, radio-immunotherapeutic and immunotherapeutic products for the treatment of various solid cancers. The company's radioisotopes are combined with carriers for optimal delivery of injected doses for the treatment of cancers. It's lead product cadherin which is an alpha-emitting radioactive microsphere designed for the treatment of metastatic cancers in peritoneal cavities. It has also developed proprietary antibodies (212Pb-labeled monoclonal antibodies) and holds a license for other antibodies.
- May 2020Series B$4M
- Feb 2017Series B$25M
- May 2016Series A$1.8M
#11
Acquired · Oslo, Oslo · founded 2014 · 16 employees$7.4Mraised▾
OncoImmunity is a bioinformatics company offering machine-learning based software to address the key knowledge gaps in the prediction of bonafide immunogenic neoantigens for personalized cancer immunotherapy. Its software provides an effective patient selection for cancer immunotherapy and identifies optimal targets for personalized cancer vaccines and cell therapies in a clinically actionable time-frame. It was a part of the Oslo Cancer Cluster Incubator.
- Oct 2021Grant (prize money)$57.8K
- May 2019Grant (prize money)$2.5M
- Dec 2018Grant (prize money)$2.5M
- Jul 2018Seed$7.4M
#12
Seed · Oslo, Oslo · founded 2014 · 3 employees$1.4Mraised▾
Developer of hand sanitizing technology for hospitals. The company has developed an automatic hand sanitizer, a disinfection cartridge, and user monitoring technology which combined improve hand hygiene for health care workers, patients, visitors, and others. This also helps in preventing hospital-acquired infections.
- May 2023Seed$1.4M
- Jan 2019Grant (prize money)$57.2K
- Aug 2018Grant (prize money)$58.3K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
What Oslo researches in biotechnology
- University of Oslo13
- Oslo University Hospital9
- Oslo Nye Høyskole1
- Oslo Cancer Cluster1
- OsloMet – Oslo Metropolitan University1
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.